Tag Archives: HEA

PR Newswire

The fourth CIIE begins taking stall reservations from exhibitors

Leave a comment

SHANGHAI, Nov. 13, 2020 — Some exhibitors planning to attend the fourth China International Import Expo (CIIE) next year started to reserve their stalls on Nov 8. This is the first time that the CIIE has offered such an option.

Five dairy companies – Fonterra, Mille, Ausnutria, Yashily and Saputo – marked their reserved booths on a map of the fourth CIIE.

Companies showcasing products at the beauty makeup section of the Consumer Goods Exhibition Area, pharmaceutical products section of the Medical Equipment & Healthcare Products Exhibition Area, and dairy products section of the Food and Agricultural Exhibition Area will receive priority when reserving their exhibition stalls, as part of new measures adopted by the fourth CIIE.

"We hope to explore a mechanism where exhibitors can choose their preferred stalls on their own starting from next year," said a worker responsible for recruiting exhibitors to the fourth CIIE.

He added that exhibitors can decide earlier to attend the expo and make preparations in advance.

The stalls at the CIIE’s Food and Agricultural Products Area have always proved to be popular among exhibitors wanting to make reservations.

The exhibition area occupied by dairy companies at the third CIIE was nearly 10,000 square meters, with six of the top eight dairy companies in the world taking part in.

The fourth CIIE’s Food and Agricultural Products Area has remained popular, with over 10 dairy companies having signed on to attend and their signed exhibition areas surpassing a total area of 5,000 square meters.

Over 120 beauty makeup and daily chemical companies have been invited to make reservations for exhibition stalls at the fourth CIIE, and many of them are currently signing agreements or making down payments.

Due to high exhibitor demand, the fourth CIIE’s beauty makeup and daily chemical product section is expected to expand to 25,000 square meters from 20,000 sq m this year.

China is the largest and most significant market for Fonterra. The CIIE has provided development opportunities for them, said Han Li, Vice-President of Fonterra Greater China, explaining why they continue to attend the expo and make reservations.

The fourth CIIE began taking applications from business exhibitors on Sept 28. It will set up six business exhibition areas: Intelligent Industry & Information Technology, Consumer Goods, Automobile, Food and Agricultural Products, Medical Equipment & Healthcare Products and Trade in Services.

Contact：Ms. Nie Qingxin

Tel.：0086-21-67008870/67008988

PR Newswire

AlpVision to offer free of charge security feature to protect COVID-19 relevant medicines against counterfeiting

Leave a comment

VEVEY, Switzerland, Nov. 13, 2020 — On November 13th, 2020, AlpVision is launching the "AlpVision COVID-19 Initiative" helping pharmaceutical companies to protect COVID-19 relevant medicines against counterfeiting.

Authentication using smartphones
Authentication using smartphones

COVID-19 has caused not only a worldwide health crisis, but also created unprecedented economic challenges. In response, AlpVision has decided to launch the "AlpVision COVID-19 Initiative". The initiative supports pharmaceutical companies by providing them for free with the necessary tools to protect COVID-19 relevant medicines and vaccines against counterfeiting.

To do so, AlpVision will provide pharmaceutical companies and their suppliers with all necessary tools to deploy the Cryptoglyph on their packaging. The AlpVision Cryptoglyph is a digital security feature which can be implemented and deployed within just a few weeks. The Cryptoglyph is invisible to the human eye and authentication of a product protected with a Cryptoglyph is done using a regular smartphone. Securing of packaging with a Cryptoglyph is very easy as it neither changes the standard production process, nor requires additional consumables. In addition, the smartphone applications connect to AlpVision’s Brand Monitoring System (BMS), a centralized server platform through which pharmaceutical companies are able to monitor in real-time product authentication activities and gain important insight into counterfeiting activities.

The "AlpVision COVID-19 Initiative" starts on November 13th, 2020, and subscription will run for an initial period of three months. Participating companies will be able to protect their COVID-19 relevant products with zero additional cost for the authentication feature. AlpVision will provide this service gratuitously until the pandemic is officially declared as ended by the World Health Organization. Companies interested in participating in the initiative are invited to contact AlpVision. More information can be found online at www.alpvision.com/Covid/.

ALPVISION – MORE THAN ANTI-COUNTERFEIT SOLUTIONS

AlpVision was founded in 2001 and is the world’s leader in digital anti-counterfeiting technologies for product authentication and counterfeit protection. AlpVision’s digital anti-counterfeiting solutions for product authentication are applicable to a wide variety of items, including packaging and labelling, plastic and metal products, and high-value documents. AlpVision anti-counterfeiting solutions are commercialized worldwide under license agreements as entirely customizable turnkey computerized systems. Today AlpVision protects over 30 billion of products each year. More information is available at www.alpvision.com. Join us on LinkedIn and follow us on Twitter.

Cryptoglyph and AlpVision are registered trademarks of AlpVision SA. Smart Embossing, AlpVision Fingerprint® and Krypsos are trademarks of AlpVision SA.

Contact:

Martin Kutter 
+41 21 948 6464  
avinfo-20@alpvision.com

Photo – https://techent.tv/wp-content/uploads/2020/11/alpvision-to-offer-free-of-charge-security-feature-to-protect-covid-19-relevant-medicines-against-counterfeiting.jpg
Logo – https://techent.tv/wp-content/uploads/2020/11/alpvision-to-offer-free-of-charge-security-feature-to-protect-covid-19-relevant-medicines-against-counterfeiting-2.jpg

  

Related Links :

http://www.alpvision.com

PR Newswire

Integrating Fitbit Wearable Devices into Diabetes Care Leads to Significant Improvements in Blood Glucose and HbA1C, Finds Health2Sync Clinical Study in Taiwan

Leave a comment
  • Wearing Fitbit devices with Health2Sync glucose control app clinically proven to help both users and healthcare providers to control and better manage the symptoms of Type 2 diabetes
  • Results from the study in Taiwan revealed an improvement in patients’ health conditions, with participants recording higher levels of physical activity, reduced HbA1C, fasting blood glucose and LDL-C, and higher blood glucose measurement frequency
  • The Health2Sync Patient Management Platform allows healthcare providers to seamlessly monitor patients’ information and provide remote consultative advice where necessary

SINGAPORE, Nov. 13, 2020 — Health2Sync, the number one diabetes management app in Taiwan and Japan, today announced the results of their clinical study in Taiwan, demonstrating that combining Fitbit wearable devices with their Health2Sync Patient Management Platform can help users control and better manage the symptoms of Type 2 diabetes mellitus (T2DM). In the study[1], conducted with four of Taiwan’s leading diabetes clinics, participants recorded significant average improvements in key indicators, such as reduced HbA1C, fasting blood glucose  and LDL-C, and higher blood glucose measurement frequency — a valuable proof of concept for using Fitbit wearables with diabetes care protocols and solutions.     

Voluntarily connecting their Fitbit Inspire HR with the Health2Sync App enabled study participants to let their doctors seamlessly monitor their information on the Health2Sync Patient Management Platform and provide remote consultative advice where necessary.
Voluntarily connecting their Fitbit Inspire HR with the Health2Sync App enabled study participants to let their doctors seamlessly monitor their information on the Health2Sync Patient Management Platform and provide remote consultative advice where necessary.

The study found:

  • Average glycated haemoglobin (HbA1C) decreased 0.33%, while patients who did moderate to high-intensity activity duration of at least 150 mins per week, saw their average HbA1C[2] decrease 0.66%
  • Average fasting blood glucose (BG) decreased 10.92 mg/dL
  • Average low-density lipoprotein cholesterol (LDL-C) decreased 11.55 mg/dL
  • Weight reduction of up to 2 kilograms among some patients
  • Increased frequency in moderate to high intensity activity to 7.03 times a week among some patients

Conducted over a three-month period ending in July 2020 in conjunction with the Neng-Chun Diabetes Clinic, Da-Ya Chang-An Clinic, Yier Clinic and Banqiao Da-Jun Clinic, the study, with patient consent, lets the patients’ doctors track the progress and lifestyle changes of 95 participants with T2DM. Prior to the commencement of the study, doctors at the four clinics established benchmarks for all participating patients based on blood glucose tests at the start of the trial, then on a self-monitored weekly basis throughout the study period.

Each participant was given a Fitbit Inspire HR and the participants voluntarily agreed to connect their Fitbit wearable data with the Health2Sync diabetes management app to track their progress throughout the program. Physical activity data generated from each person’s Fitbit device was integrated into the Health2Sync app, which housed other health metrics such as patients’ HbA1c, BG and cholesterol levels. This let doctors seamlessly monitor patients’ information on the Health2Sync Patient Management Platform and provide remote consultative advice where necessary.

Dr. Kuo-Liang Lu of Da-Ya Chang-An Clinic in Taiwan, said: "The results speak for themselves. We saw a reduction in some of our patients’ weight by an average of two kilograms and fasting BG levels of study participants from Da-Ya Chang-An clinic decreased 11.10 mg/dL within 3 months[3], leading to significant health improvements."

Dr. Neng-Chu Yu of Neng-Chun Diabetes Clinic said: "Type 2 diabetes, with the right lifestyle changes – medication adherence, increased activity, and better diet – can lead to major improvements in control of blood glucose levels. The integration of Fitbit data with Health2Sync let me easily view my patients’ activities and self-monitored data, enabling me to make necessary suggestions and give guidance to help patients for further improvement."

Diabetes is a chronic condition that, if not managed, can lead to health complications like blindness, kidney failure, heart attacks, stroke and lower limb amputation.[4] It remains the second highest cause in premature mortality, after cancer, among major non-communicable diseases in Taiwan[5] and its prevalence has posed economic burdens such as increased personal and healthcare spending and loss of work productivity.[6]

A holistic approach to managing T2DM requires lifestyle changes, which includes medication adherence, exercise and proper diet. The integration with Fitbit wearable devices and activity data is key to helping to promote healthier behaviours and improve participants’ health outcomes. Participants received reminders for weekly exercises via their Health2Sync App, which promoted an increased frequency in moderate to high intensity activity at 7.03 times a week. The increased levels of activity corresponded with an improvement in patients’ health conditions.

"We are thrilled to see such optimistic results in the clinical study. We believe that innovations in Fitbit wearable devices and Fitbit health solutions have a major role to play in the global effort against diabetes – whether it is in reducing the onset of diabetes, or helping patients to better manage their condition – and we look forward to further expanding on our partnership with Fitbit," said Ed Deng, CEO at Health2Sync.

"The behavioural changes exhibited by study participants reinforces our belief that Fitbit amplifies our intrinsic motivation to adopt healthier habits, which can make all the difference when dealing with a condition like Type 2 diabetes where lifestyle factors play such a big role," said Steve Morley, Vice President of International Health Solutions & General Manager of Asia Pacific at Fitbit. "Together with the seamless experience that Health2Sync provides for patients and their health providers to track key indicators, they create a powerful solution that makes it simpler and more convenient to manage conditions like Type 2 diabetes."

In September last year, Fitbit and Health2Sync collaborated to allow the integration of Fitbit’s health, sleep and fitness wearable data with the Health2Sync app (with user consent) to support Health2Sync’s 520,000 users in Japan and Taiwan to better manage their conditions, like Type 2 diabetes. The new platform gives users who have a Fitbit account access to an in-app dashboard that includes the option to agree to share their wearable data from their Fitbit devices[7], including heart rate, sleep and physical activity, alongside recent blood glucose readings from Health2Sync depicting if levels fall within, above, or below the healthy range.

[1] The study was conducted on 95 participants, ages 18- 60.

[2] The term HbA1c refers to glycated haemoglobin. Diabetics with higher levels of HbA1c face greater risk of developing diabetes-related complications.

[3] Average fasting blood glucose levels of study participants from Da-Ya Chang-An clinic decreased 11.10 mg/dL compared to the study average of 10.92 mg/dL

[4] "Diabetes" World Health Organization, 2020. https://www.who.int/news-room/fact-sheets/detail/diabetes.

[5] IC Chen., Yu NC. "A Decade of Diabetes Care in Taiwan." Diabetes research and clinical practice. U.S. National Library of Medicine, 2014. https://pubmed.ncbi.nlm.nih.gov/25550058/.

[6] Wong LC., Tsai CY., Chou HK., Tsai MT., Tsai WH., Chou.P., and Shen ST. "Healthcare costs associated with progressive diabetic retinopathy among National Health Insurance enrollees in Taiwan, 2000-2004." BMC Health Services Research, May 26, 2010. https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-10-136

[7] Includes Fitbit Sense, Fitbit Versa 3, Fitbit Charge 4, Fitbit Inspire 2, among others.

About Health2Sync

Health2Sync scales diabetes care by providing a digital engagement platform that is comprised of a mobile App for diabetics, cloud-based analytics, and cloud platform for healthcare providers. The smart analytics algorithms provide users with personalized education and guidance based on their biometric and behavior data captured. With the cloud platform, healthcare providers can easily take control of patients’ condition through the analyzed data.

Health2Sync is the largest diabetes management platform in Asia (excl. China) and proven to help users improve their outcome.  Health2Sync has supported partners including pharmaceuticals, private payers, and the public payor to provide diabetics with innovative services.  In 2017, 2018 and 2019 Health2Sync was selected as Top 10 Diabetes App globally by Healthline.

PR Newswire

For 2020, The World Innovation Summit for Health (WISH) Delivers Leading Speakers and Compelling Discussions via an Immersive Virtual Platform

Leave a comment

DOHA, Qatar, Nov. 9, 2020 — The World Innovation Summit for Health (WISH) returns on 15 November, 2020, offering an impressive range of speakers, networking opportunities, discussions and presentations that explore global health challenges, and – all presented through a purpose-built 3D virtual platform.

Oscar-winning actor, humanitarian and activist, Morgan Freeman, keynote speaker at the World Innovation Summit for Health 2020 (Photo credit: Nigel Parry)
Oscar-winning actor, humanitarian and activist, Morgan Freeman, keynote speaker at the World Innovation Summit for Health 2020 (Photo credit: Nigel Parry)

In light of the current pandemic, the biennial global gathering of healthcare leaders is being held online, will be free to attend and, for the first time, members of the public are being invited to register. Additionally, WISH 2020 will take place over five days rather than the usual two, running from 15-19 November.

COVID-19 will feature prominently, as will a range of other global health challenges, including climate change and health, childhood toxic stress, mental health and digital technologies, and immunotherapy.

Confirmed speakers include the WHO director general, Dr. Tedros Adhanom Ghebreyesus; Sweden’s chief epidemiologist, Dr. Anders Tegnell; WHO COVID-19 special envoy, Dr. David Nabarro; award-winning, Sudan-based medic and humanitarian, Dr. Tom Catena; and California’s surgeon general Dr. Nadine Burke Harris.

Actor, activist and philanthropist Eva Longoria will add her voice to the discussions around the impact of the pandemic and global health inequalities experienced by women and girls of color. Iconic Oscar-winning actor Morgan Freeman will give a keynote speech around the topic of the need to focus on early childhood health in a world struggling to combat global warming and conflict.

More than 300 speakers and panelists have been confirmed so far, with more to be announced in the lead-up to the event.

Innovators and health entrepreneurs will be showcased in an expansive ‘Innovation Hub’ exhibition space, which will also feature organizations committed to building a healthier world, including The Carter Center, Save The Children, and UNICEF.

The WISH platform will also feature a library, a cinema, a networking area, and a wellness zone.

Sultana Afdhal, CEO of WISH, said: "This year more than ever, we have witnessed the importance of collaborating to tackle global health challenges. While we’re disappointed not to be able to welcome visitors to a physical event in Doha, we are looking forward to virtually welcoming many more people to WISH than would normally be possible."

WISH is an initiative of Qatar Foundation. More details regarding the summit, including details of how to register, can be found at www.wish.org.qa

Photo – https://mma.prnasia.com/media2/1329348/world_innovation_summit_morgan_freeman.jpg?p=medium600

 

PR Newswire

Healthscope selects Adoreboard to improve Patient Experience in a Post-COVID World

Leave a comment

BELFAST, Ireland, Nov. 5, 2020 — AI is being used to understand patients’ emotions to help detect breaches in COVID-19 across 43 Healthscope hospitals in Australia with the deployment of Emotion AI technology Adoreboard.

As hospitals wrestle with the challenge of COVID-19, Healthscope a leading private healthcare provider, with 43 private hospitals across Australia and New Zealand treating 600,000 patients annually, has turned to Emotion AI platform Adoreboard to understand patient emotions.

Insights by Healthscope using Adoreboard shows that apprehension spiked by 33% during the lockdown period as patients came to terms with the pandemic with 12.5% of all COVID-19 related comments expressed concerns around social distancing in areas such as hospital lifts.  

It also pinpointed the need for multi-language signage with this issue alone driving patient sadness by 30%. In response, Healthscope’s patient experience and communications team rolled out innovative signage on social distancing instructions on thousands of meal trays across all hospitals with social distancing messaging for patients in multiple languages. A week after implementing the modifications they saw the positive changes in the patient feedback through the Emotion AI technology.

The software works by automatically integrating patient feedback from Qualtrics into Adoreboard’s Emotics platform which can detect 24 levels of emotional intensity. Adoreboard’s AI can detect recurring themes that trigger emotions such as Joy or Anger which in turn helps Healthscope prioritise what actions to take.

Jeffrey Woods, National Patient Experience Manager at Healthscope said: "Adoreboard’s Emotics helps our frontline staff connect the dots in far more meaningful and empathetic ways. This improves speed to insight and ultimately the patient outcome by enabling us to prioritise decisions based on emotional intensity in any feedback. The best in human experience should be at the heart of healthcare and that’s why we use Adoreboard."

The technology has also been deployed to detect other issues impacting patient experience by providing predictions on the outcome on its patient experience metrics if resolved. 

One such issue was the impact of blood monitoring cuffs which if fitted wrongly can cause discomfort to a patient’s arm. The AI identified this issue reduced patient trust by 33% and increased sadness by 88%. The analysis showed by fixing this issue gains in satisfaction levels of patient experience would increase by 18%.

Adoreboard is a Gartner Cool Vendor in Customer Analytics using AI.

 

PR Newswire

Nel ASA: Selected by Iberdrola as preferred supplier for a 20 MW green fertilizer project in Spain

Leave a comment

OSLO, Norway, Nov. 4, 2020 — Nel Hydrogen Electrolyser, a division of Nel ASA (Nel, OSE:NEL), has been selected as preferred supplier by Iberdrola for a 20 MW PEM solution for a green fertilizer project in Spain. Contract award is subject to mutual agreement on the final commercial terms. The hydrogen plant is scheduled to commence operations in 2021.

"We are very excited and honored that Iberdrola prefer to use a PEM electrolyser solution from Nel for this landmark green fertilizer project. It is a true testament to our PEM platform, which has been deployed all over the world for several decades. We continuously work to develop larger systems, and with this project our PEM platform will be designed into a 20 MW solution. We have over the course of the last year been working on both alkaline and PEM large-scale solutions, which serve different customer needs, and we look forward to provide our PEM solution for this project," says Filip Smeets, SVP Nel Hydrogen Electrolyser, Nel Hydrogen Fueling.

Iberdrola, one of the largest electricity utilities in the world, has together with a world-leading fertilizer manufacturer Fertiberia launched a project to establish the largest green hydrogen plant in Europe. Located in Puertollano, Spain it will feature a 100 MW photovoltaic plant, a battery installation with a storage capacity of 20 MWh, and a 20 MW electrolyser. The hydrogen produced in the project will primarily be used for green fertilizer production. The 20 MW electrolyser is scheduled to commence operations in 2021.

Contract award is subject to mutual agreement on the final agreement on terms and conditions, technical details, and board approval.

For further information, please contact:

Jon André Løkke, CEO, +47 907 44 949

Kjell Christian Bjørnsen, CFO, +47 917 02 097

About Nel ASA | www.nelhydrogen.com

Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store, and distribute hydrogen from renewable energy. We serve industries, energy, and gas companies with leading hydrogen technology. Our roots date back to 1927, and since then, we have had a proud history of development and continuous improvement of hydrogen technologies. Today, our solutions cover the entire value chain: from hydrogen production technologies to hydrogen fueling stations, enabling industries to transition to green hydrogen, and providing fuel cell electric vehicles with the same fast fueling and long range as fossil-fueled vehicles – without the emissions.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nel-asa/r/nel-asa–selected-by-iberdrola-as-preferred-supplier-for-a-20-mw-green-fertilizer-project-in-spain,c3230644

The following files are available for download:

PR Newswire

Clarivate Expands International Real-World Data Offering with Addition of Techtrials Brazilian Dataset

Leave a comment

Partnership to provide life science, healthcare and research professionals with comprehensive RWD capturing approximately 80% of the Brazilian population

LONDON, Nov. 2, 2020 — Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the expansion of international real-world data offerings through its partnership with Techtrials Pesquisa e Tecnologia Ltda (Techtrials), the leading healthcare real-world data (RWD) provider in Brazil. The new partnership will provide customers with comprehensive RWD capturing approximately 80% of the Brazilian population.

As part of the three-year partnership, Clarivate customers can access the largest integrated real-world database in Brazil to address the most pressing questions related to epidemiological, clinical and pharmacoeconomic outcomes. The dataset features in-depth, clinically structured, anonymized data of billions of records with more than 195 million patients in the public and private market as well as claims, electronic medical records, registry and lab data. The comprehensive Techtrials real-world data paired with the expertise, information and insights that power DRG healthcare products and services, will allow global researchers to access, synthesize and analyze critical data.

The Techtrials dataset will be available to life sciences companies internationally, supporting a multitude of end users, to enable deeper insights and delivery of complex and high value use cases.  Clients can choose from an array of delivery options depending on their resource needs and expertise, including: commercial targeting; patient population & market sizing; patient journey; therapeutic area assessments; disease burden analysis; health economics and outcomes research and more.

As the world’s 11th largest pharmaceutical market, Brazil spends 9.5 percent of GDP on healthcare – providing universal healthcare to its population.1 Multinational pharmaceutical companies continue to invest and expand operations in Brazil, with market researchers anticipating spending to increase at a compound annual growth rate of 7% to 10% from 2018–2022.2 Clarivate recognizes the ever-increasing need for customers within the Latin American market to have insights-ready RWD on a real-time basis to help drive and inform decision-making.

Ken McLaren, SVP & GM of Data, Analytics and Insights for Clarivate, said: "We appreciate the complexity of healthcare and the diversity of decisions its leaders must make, especially in an international context. We look forward to partnering with an organization like Techtrials to help our customers understand and drive decision-making with confidence in the high growth, high interest Brazilian market."

Douglas Andreas Valverde, CEO, Techtrials, said: "As a regional innovation leader for data solutions and real-world evidence, we offer a unique mix of capabilities and proprietary technology, providing valuable clinical and real-world evidence insights to support the efforts of pharmaceutical, healthcare and government agencies. We are proud to partner with Clarivate to reach international industry stakeholders who need to act and make critical decisions in their daily operations."

The Brazilian RWD offering features insights, including: new professionals per institution; variation of patients per period; procedures; workload by institution; comprehensive disease, epidemiology and market knowledge; drug use by specialty; outcomes, hospitalizations, surgeries and sub-procedures; hospital and comorbidities and more. The incorporation of Techtrials data further reinforces the expertise provided by Clarivate to support customers across the entire drug, device and medical technology lifecycles.

To learn more, visit https://clarivate.com/drg/real-world-data.

About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.

Media Contact
Catherine Daniel
media.enquiries@clarivate.com

1National Health Account (NHA) Indicators 2020. Source: Global Health Expenditure Database (GHED) of the World Health Organization.
2"Brazil: Commercialization Outlook, Global Market Access Solutions" 2020. Source: DRG, part of Clarivate

Logo – https://techent.tv/wp-content/uploads/2020/11/clarivate-expands-international-real-world-data-offering-with-addition-of-techtrials-brazilian-dataset.jpg

Related Links :

Home
PR Newswire

VeChain, Renji Hospital and DNV GL Held Strategic Partnership Signing Ceremony To Launch World’s First Blockchain Intelligent Tumor Treatment Center

Leave a comment

SHANGHAI, Oct. 27, 2020 — In partnership with VeChain and DNV GL, Renji Hospital, a top-ranked hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has announced the launch of the world’s first blockchain-enabled Intelligent Tumor Treatment Center on October 20, 2020. The Intelligent Tumor Treatment Center is a transparent, efficient, and traceable medical management solution powered by VeChain ToolChainTM.

Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group
Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group

As strategic partners of this new initiative, VeChain and DNV GL will jointly support the hospital in the quest to improve global public health through state-of-the-art blockchain technology and professional advisory.

VeChain ToolChainTM Powers The World’s First Intelligent Tumor Treatment Center 

The Intelligent Tumor Treatment Center combines the advantages of VeChain blockchain technology with DNV GL’s professional services. It enables full patient ownership of personal medical records, allowing patients to take control of the authorization and medical records data management. Research institutions inside and outside the hospital can use authorized data to improve the efficiency of clinical research, and regulatory agencies can use authorized data to conduct business compliance checks on medical institutions and establish a credit evaluation system.

Zhang Jidong, Vice President of Renji Hospital, said, "The launch of the Intelligent Tumor Treatment Centre intends to enhance high-quality integrated development of Renji Hospital. Moving forward, Renji intends to boost our healthcare facilities with more blockchain-powered use cases and projects, which will be gradually disclosed together with our partners when the time is right."

George Kang, Senior Vice President of DNV GL Group, said, "Through independent and objective medical evaluation methods, DNV GL intends to provide more services for Renji Hospital to improve its service quality and medical experience, moving to a new stage of higher standards, higher requirements and higher quality."

Sunny Lu, co-founder and CEO of VeChain, said, "As digital transformation accelerates in the healthcare sector, VeChain will continue to demonstrate its advantages and flexibility as a superior blockchain platform that is suitable for all types of use cases and industries. We are very proud and excited to be contributing to the public health industry by providing the technology for Renji Hospital’s Intelligent Tumor Treatment Centre."

VeChain Facilitating Digital Transformation To Improve Public Health

In line with the Chinese Government’s 14th Five-Year (2021-2025) Plan for Economic and Social Development, the National Health Commission formulated an official guideline and re-emphasized blockchain technology as an essential innovation and integration of the medical and health industry. VeChain is committed to solving the pain points of digital medical reform through blockchain technology and balancing personal privacy and public interests.

By using the self-developed one-stop data BaaS platform VeChain ToolChainTM , we have many proven cases in the medical sector, including a blockchain powered Clinical Trial Traceability Platform for Bayer China, and a blockchain-enabled medical data management platform named The E-NewHealthLife for Mediterranean Hospital of Cyprus. Facing new demands for digital transformation brought by COVID-19, VeChain, together with DNV GL, will be seeking for more opportunities to create more high-efficiency and low-cost digital solutions for the medical industry.

About VeChain
Launched in 2015, VeChain connects blockchain technology to the real world by providing a comprehensive governance structure, a robust economic model, and IoT integration. VeChain is the pioneer of real-world applications using public blockchain technology, with international operations in Singapore, Luxembourg, Tokyo, Shanghai, Paris, Hong Kong, and San Francisco. Together with our strategic partners PwC and DNV GL, we have established cooperative relations with many leading enterprises in different industries, including Walmart China, BMW, BYD Auto, Haier, H&M, LVMH, D.I.G, ENN, Shanghai Gas, AWS, PICC, ASI etc. Website: www.vechain.com

About Renji Hospital
Built in 1844, Renji Hospital has a history of over 170 years. It has been the first western medicine hospital since the opening of Shanghai. With an integration of medical treatment, teaching and scientific research, it is a comprehensive 3A hospital (the top level of hospital ranking in China) with a complete range of disciplines. Up to now, Renji Hospital consists of five  areas in total. Below is the timeline of the development process of Renji Hospital.

About DNV GL
DNV GL is a leading provider of risk management and quality assurance services. The company is also a global leader in certifying management systems of companies across all types of industries, including F&B. Since 1864, its purpose has been to safeguard life, property and the environment. Passionate about safety, quality and integrity, companies turn to DNV GL to make complex decisions with confidence. DNV GL helps them manage their most critical risks and demonstrate compliance with regulations and standards.

Photo – https://techent.tv/wp-content/uploads/2020/10/vechain-renji-hospital-and-dnv-gl-held-strategic-partnership-signing-ceremony-to-launch-worlds-first-blockchain-intelligent-tumor-treatment-center.jpg
Logo – https://techent.tv/wp-content/uploads/2020/10/vechain-renji-hospital-and-dnv-gl-held-strategic-partnership-signing-ceremony-to-launch-worlds-first-blockchain-intelligent-tumor-treatment-center-2.jpg

 

Related Links :

http://www.vechain.com

PR Newswire

CaDi introduces Lycofertilic™ – high potency, targeted supplements with algae DHA Omega-3 to provide anti-ageing support for the ovarian reserve and to prepare for egg retrieval and IVF

Leave a comment

LONDON, Oct. 23, 2020 — Cambridge Diagnostic Imaging (CaDi) is launching a new generation of targeted daily supplements, LycofertilicTM for fertility support and LycofertilicTM Prime to prepare for egg retrieval and IVF.

The ovarian reserve and egg quality of women declines with age. This depletion is exacerbated by stress, imbalanced diet and obesity and is further deteriorated by inflammatory pathologies of the pelvic organs. These processes, even on a subclinical asymptomatic level, are amogst the main factors negatively affecting natural or artificial fertilisation processes and pregnancy.

Lycofertilic™ has been developed by Lycotec, a company in Cambridge, UK. It is a patented complex of DHA Omega-3, Lutein and Zeaxanthin, which, due to patented technology, helps to provide anti-ageing support for the ovarian reserve in women throughout their fertility years.

It is very important to improve the quality of the egg in its preparation for retrieval and IVF. Lycofertilic™ Prime is an increased dose of this complex developed especially to boost this process.

Clinical trials (link below) demonstrated 250 mg of Lycofertilic™ DHA Omega 3 to be 10-16 times stronger than conventional Omega 3 supplement products and 4–5 times more powerful than Omega 3 pharmaceuticals. This superiority translates into a much more efficient reduction in markers of inflammatory damage and to a boost in peripheral tissue oxygenation and respiration. The increased bioavailability and targeted delivery reduces side effects and makes for unnecessary overconsumption of traditional Omega 3 products.

"According to the World Health Organisation 28 million women around the world encounter fertility problems every year. This is a serious problem which we decided to help to address by launching these new innovative technology-based products. As preparation for IVF is a critical period for the fertilisation process, it is of utmost importance that women receive health products with the highest quality ingredients such as algae DHA Omega-3, and of sustainable origin too" said Alexey Shulepov, CEO of CaDi.

A combination of Lycofertilic™ products with a personalised CaDi AI-based algorithm recommendation provides additional superior efficacy over existing Omega 3. Both Lycofertilic™ products are safe, vegan and their active ingredients are GMO-free and approved for humans.

About CaDi and Lycofertilic™:

http://cambridgediagnostics.co.uk – CaDi official website, online store of Lycofertilic™

lycotec.com – medical research company, developer of technologies of Lycofertilic™ 

https://www.ijabmr.org/article.asp?issn=2229-516X;year=2018;volume=8;issue=3;spage=148;epage=154;aulast=Petyaev – Clinical trials

For any questions please contact – pr@cambridgediagnostics.co.uk

PR Newswire

Deep Longevity and Longenesis to Partner on Consent Management Integration and Federated Learning Method Development

Leave a comment

HONG KONG, Oct. 23, 2020 — Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; SEHK:0575.HK) today announced that Deep Longevity, Inc,, a company recently acquired by the Group which mainly engaged in the development of explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels, has entered into a partnership with Longenesis, a leader in consent-enabled safe data curation for research. Two companies will partner on the integration of the consent management system developed by Longenesis into the Deep Longevity digital platform including Young.AI, a web-based tracker of aging and wellness, and the development of a federated learning framework.

Deep Longevity scientists are the original inventors of the "deep aging clocks", multimodal biomarkers of aging developed using deep learning techniques with multiple granted patents. They recently published deep hematological aging clocks, deep transcriptomic and proteomic aging clocks, deep microbiomic aging clocks, and contributed to the development of the photographic aging clocks.

Longenesis has created an end-to-end environment for biomedical institutions, patient organizations and research partners and sponsors – to communicate directly, enabling both safe data curation and compliant, consent-enabled biomedical data utilization for research.

"At Deep Longevity we are working on creating a network of hospitals and clinics that will have access to our aging clocks. To enable this network, we are aiming to create a federated learning pipeline, that will allow us to train multiple new aging clocks without the need to transfer user data", explains Polina Mamoshina, Ph.D., Chief Scientific Officer of Deep Longevity, a Regent Pacific company.

"Longenesis is a company invested by LongeVC, a venture fund, and accelerator dedicated to growing the longevity ecosystem in the European Union. Over the past few years, Longenesis developed a range of technologies to help protect user privacy and manage consent to help companies provide the individuals with more tools to take control over their data", said Garry Zmudze, founding partner of LongeVC, an investor in both Longenesis and Deep Longevity.

"At Longenesis we believe that the need for centralized, compliant and seamless biomedical data asset identification is crucial for collaborative research initiation, faster patient recruitment and timely response to global healthcare challenges. We are looking forward to this collaboration, creating a federated learning pipeline and embracing the "data stays local" principle at the same time", says Sergejs Jakimovs, a CEO of Longenesis.

– Ends –

This press release is distributed by LBS Communications Consulting Limited.

About Deep Longevity

Deep Longevity has been acquired by Regent Pacific (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other experts AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.

http://longevity.ai/

About Regent Pacific (SEHK:0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

http://www.regentpac.com/

About Longenesis

Longenesis Ltd. is a software technology company, that is focused on developing legitimate ways to promote collaboration between biomedical institutions, patient organizations and research partners by identifying biomedical data from metadata files, by onboarding population cohorts and by engaging new patients in the research.

https://longenesis.com/

About LongeVC

LongeVC is an investment group, specialising in curating, facilitating and executing early stage venture investments in the fields of biotech and longevity. Current investment portfolio of LongeVC includes Insilico Medicine, a global leader in AI-driven drug discovery, Longenesis, an end-to-end collaborative biotech research enabler, Basepaws, the first comprehensive DNA sequencing solution for pets, as well as other biotech industry-specific companies. With its latest exit, LongeVC has announced the creation of its first official early-stage investment fund, focused on biotech and longevity opportunities, with backing from the most prominent advisory board in the longevity industry.